<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <!-- Google tag (gtag.js) -->
<script async src=“https://www.googletagmanager.com/gtag/js?id=G-266CNVJKNE”></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag(‘js’, new Date());
  gtag(‘config’, ‘G-266CNVJKNE’);
</script>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Executive Summary | RCC Therapeutics Report 2025–2035</title>
    <meta name="description" content="Executive summary of the Refractory Chronic Cough therapeutics market. $9B market with 100M patients worldwide, zero FDA-approved drugs, and digital therapeutics emerging as key value drivers.">
    <meta name="keywords" content="refractory chronic cough executive summary, RCC market overview, chronic cough therapeutics, P2X3 antagonists, digital therapeutics cough">
    <link rel="icon" type="image/png" href="favicon.png">
    
    <!-- Open Graph -->
    <meta property="og:title" content="Executive Summary | RCC Therapeutics Report">
    <meta property="og:description" content="Key findings from the comprehensive analysis of the $9B+ Refractory Chronic Cough therapeutics market.">
    <meta property="og:type" content="article">
    
    <!-- Fonts -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Fraunces:ital,opsz,wght@0,9..144,300;0,9..144,500;0,9..144,700;1,9..144,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet">
    
    <style>
        :root {
            --forest: #1a4d3e;
            --forest-dark: #0f2f26;
            --forest-light: #2a6b58;
            --coral: #e85a4f;
            --coral-light: #ff7b6b;
            --cream: #faf8f5;
            --warm-white: #fffefa;
            --text-primary: #1a1a1a;
            --text-secondary: #4a4a4a;
            --text-muted: #6b6b6b;
        }
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        html {
            scroll-behavior: smooth;
        }
        
        body {
            font-family: 'Source Sans 3', -apple-system, sans-serif;
            background: var(--cream);
            color: var(--text-primary);
            line-height: 1.7;
            font-size: 17px;
        }
        
        h1, h2, h3, h4 {
            font-family: 'Fraunces', Georgia, serif;
            font-weight: 500;
            line-height: 1.3;
        }
        
        .container {
            max-width: 800px;
            margin: 0 auto;
            padding: 0 24px;
        }
        
        /* Header */
        .header {
            background: var(--forest-dark);
            padding: 16px 0;
            position: sticky;
            top: 0;
            z-index: 100;
        }
        
        .header__inner {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .header__badge {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            color: white;
            font-size: 14px;
            font-weight: 500;
            letter-spacing: 0.05em;
            text-decoration: none;
        }
        
        .header__badge:hover {
            opacity: 0.9;
        }
        
        .header__badge span {
            background: var(--coral);
            padding: 4px 10px;
            font-size: 11px;
            letter-spacing: 0.1em;
            text-transform: uppercase;
        }
        
        .header__cta {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            background: var(--coral);
            border: none;
            color: white;
            padding: 12px 24px;
            font-size: 14px;
            font-weight: 600;
            cursor: pointer;
            text-decoration: none;
            transition: background 0.2s;
        }
        
        .header__cta:hover {
            background: var(--coral-light);
        }
        
        .header__cta svg {
            width: 16px;
            height: 16px;
            fill: currentColor;
        }
        
        /* Hero */
        .hero {
            background: linear-gradient(165deg, var(--forest) 0%, var(--forest-dark) 100%);
            padding: 60px 0 80px;
            position: relative;
        }
        
        .hero::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 600px;
            height: 600px;
            background: radial-gradient(circle, rgba(232,90,79,0.12) 0%, transparent 70%);
            pointer-events: none;
        }
        
        .hero__label {
            display: inline-block;
            background: var(--coral);
            color: white;
            padding: 6px 14px;
            font-size: 12px;
            font-weight: 600;
            letter-spacing: 0.1em;
            text-transform: uppercase;
            margin-bottom: 20px;
        }
        
        .hero__title {
            color: white;
            font-size: clamp(2rem, 4vw, 3rem);
            font-weight: 500;
            margin-bottom: 16px;
        }
        
        .hero__subtitle {
            color: rgba(255,255,255,0.8);
            font-size: 1.15rem;
            max-width: 600px;
        }
        
        /* Big Picture Box */
        .big-picture {
            background: linear-gradient(135deg, var(--forest) 0%, var(--forest-dark) 100%);
            padding: 48px;
            margin: -40px auto 60px;
            max-width: 800px;
            position: relative;
            z-index: 10;
            box-shadow: 0 20px 60px rgba(0,0,0,0.15);
        }
        
        @media (max-width: 600px) {
            .big-picture {
                padding: 32px 24px;
                margin: -30px 16px 40px;
            }
        }
        
        .big-picture__label {
            color: var(--coral-light);
            font-size: 13px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.1em;
            margin-bottom: 16px;
        }
        
        .big-picture__title {
            color: white;
            font-size: 1.75rem;
            margin-bottom: 24px;
        }
        
        .big-picture p {
            color: white;
            margin-bottom: 16px;
            font-size: 1.05rem;
        }
        
        .big-picture p:last-child {
            margin-bottom: 0;
        }
        
        .big-picture strong {
            color: var(--coral-light);
        }
        
        /* Main Content */
        .content {
            padding: 0 0 80px;
        }
        
        .content__section {
            margin-bottom: 48px;
        }
        
        .content__section:last-child {
            margin-bottom: 0;
        }
        
        .content__number {
            font-family: 'Fraunces', serif;
            font-size: 3rem;
            color: var(--coral);
            font-weight: 700;
            opacity: 0.3;
            line-height: 1;
        }
        
        .content__title {
            font-size: 1.5rem;
            color: var(--forest-dark);
            margin-top: -10px;
            margin-bottom: 20px;
        }
        
        .content p {
            color: var(--text-secondary);
            margin-bottom: 16px;
        }
        
        .content ul {
            color: var(--text-secondary);
            padding-left: 24px;
            margin-bottom: 16px;
        }
        
        .content li {
            margin-bottom: 10px;
        }
        
        .content strong {
            color: var(--text-primary);
        }
        
        /* Highlight inline */
        .highlight {
            background: rgba(232,90,79,0.1);
            padding: 2px 6px;
            border-radius: 3px;
        }
        
        /* Stats Grid */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
            margin: 32px 0;
        }
        
        @media (max-width: 500px) {
            .stats-grid {
                grid-template-columns: 1fr;
            }
        }
        
        .stat-card {
            background: white;
            padding: 24px;
            border-left: 4px solid var(--forest);
        }
        
        .stat-card--highlight {
            border-left-color: var(--coral);
        }
        
        .stat-card__number {
            font-family: 'Fraunces', serif;
            font-size: 2rem;
            color: var(--forest);
            font-weight: 700;
            line-height: 1;
            margin-bottom: 8px;
        }
        
        .stat-card--highlight .stat-card__number {
            color: var(--coral);
        }
        
        .stat-card__label {
            font-size: 14px;
            color: var(--text-muted);
        }
        
        /* CTA Section */
        .cta-section {
            background: var(--forest-dark);
            padding: 60px 0;
            text-align: center;
        }
        
        .cta-section__title {
            color: white;
            font-size: 1.75rem;
            margin-bottom: 16px;
        }
        
        .cta-section__text {
            color: rgba(255,255,255,0.7);
            margin-bottom: 32px;
            max-width: 500px;
            margin-left: auto;
            margin-right: auto;
        }
        
        .cta-section__btn {
            display: inline-flex;
            align-items: center;
            gap: 10px;
            background: var(--coral);
            color: white;
            padding: 16px 32px;
            font-size: 16px;
            font-weight: 600;
            text-decoration: none;
            transition: background 0.2s;
        }
        
        .cta-section__btn:hover {
            background: var(--coral-light);
        }
        
        .cta-section__btn svg {
            width: 20px;
            height: 20px;
            fill: currentColor;
        }
        
        /* Footer */
        .footer {
            background: var(--forest-dark);
            padding: 32px 0;
            border-top: 1px solid rgba(255,255,255,0.1);
        }
        
        .footer__inner {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 16px;
        }
        
        .footer__text {
            color: rgba(255,255,255,0.5);
            font-size: 14px;
        }
        
        .footer__links {
            display: flex;
            gap: 24px;
        }
        
        .footer__links a {
            color: rgba(255,255,255,0.5);
            text-decoration: none;
            font-size: 14px;
            transition: color 0.2s;
        }
        
        .footer__links a:hover {
            color: white;
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header class="header">
        <div class="header__inner">
            <a href="index.html" class="header__badge">
                <span>Report</span>
                RCC Therapeutics 2025–2035
            </a>
            <a href="index.html#gate" class="header__cta">
                <svg viewBox="0 0 24 24"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z"/></svg>
                Download Full Report
            </a>
        </div>
    </header>
    
    <!-- Hero -->
    <section class="hero">
        <div class="container">
            <span class="hero__label">Executive Summary</span>
            <h1 class="hero__title">Refractory Chronic Cough Therapeutics</h1>
            <p class="hero__subtitle">Pipeline Analysis & Competitive Landscape 2025–2035</p>
        </div>
    </section>
    
    <!-- The Big Picture -->
    <div class="big-picture">
        <div class="big-picture__label">The Big Picture</div>
        <h2 class="big-picture__title">A Market at Decisive Inflection Point</h2>
        <p>The RCC landscape is at a decisive inflection point. If approved by the FDA, drugs in the pipeline will unlock a substantial and underserved category, but clinical, regulatory, and payer expectations have risen materially following prior failures.</p>
        <p>Across all mechanisms, <strong>placebo-adjusted efficacy, durability, and real-world evidence</strong> are now the determinants of success.</p>
        <p><strong>Digital therapeutics represent a major, underrecognized source of value creation.</strong> They expand access, reduce toxicity, generate real-world data, and improve the economic viability of pharmacologic launches.</p>
        <p>In a market defined by high unmet need but high evidentiary burden, the winners will be those who combine <strong>validated mechanisms, tolerability, durability, and digital integration</strong> into a unified, evidence-driven treatment model.</p>
    </div>
    
    <!-- Main Content -->
    <main class="content">
        <div class="container">
            
            <!-- Market Overview -->
            <section class="content__section">
                <div class="content__number">01</div>
                <h2 class="content__title">Market Overview</h2>
                
                <p>Refractory Chronic Cough (RCC) remains a large, undertreated, and globally unaddressed condition. Despite an estimated <strong>100 million affected worldwide</strong> and ~10 million in the U.S., there are no FDA-approved therapies.</p>
                
                <p>Current practice relies on off-label medicines with <span class="highlight">31–40% adverse event rates</span>, modest efficacy, and limited persistence. The first U.S. approval—expected no earlier than 2026—will create a new therapeutic category but will enter into a market shaped by high placebo response, demanding regulators, and increasing payer scrutiny.</p>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-card__number">450–600M</div>
                        <div class="stat-card__label">Global chronic cough prevalence</div>
                    </div>
                    <div class="stat-card stat-card--highlight">
                        <div class="stat-card__number">~100M</div>
                        <div class="stat-card__label">Global RCC patients</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-card__number">20–30M</div>
                        <div class="stat-card__label">Commercially reachable patients</div>
                    </div>
                    <div class="stat-card stat-card--highlight">
                        <div class="stat-card__number">~$9B → $15B</div>
                        <div class="stat-card__label">Market size 2024 → 2035</div>
                    </div>
                </div>
                
                <p><strong>Growth Drivers:</strong> Aging populations, specialist referral expansion, digital identification tools, and increasing recognition of cough hypersensitivity.</p>
                
                <p>The U.S. market will likely see one winner, at most two, with meaningful time separation between market entries.</p>
            </section>
            
            <!-- Regulatory Reset -->
            <section class="content__section">
                <div class="content__number">02</div>
                <h2 class="content__title">Regulatory Reset</h2>
                
                <p>Two Complete Response Letters (CRL) for Gefapixant (January 2022 and December 2023) materially raised the evidentiary bar:</p>
                
                <ul>
                    <li>The FDA requires a <strong>≥30% placebo-adjusted reduction</strong> in objective 24-hour cough frequency</li>
                    <li>Clinically meaningful improvements in patient-reported outcomes are mandatory</li>
                    <li>The high placebo response threatens statistical separation for all mechanisms</li>
                </ul>
                
                <p>Without stronger Health Economics and Outcomes Research (HEOR) evidence, even efficacious therapies may see restricted access or price compression.</p>
            </section>
            
            <!-- Mechanism Performance -->
            <section class="content__section">
                <div class="content__number">03</div>
                <h2 class="content__title">Mechanism Performance and Competitive Landscape</h2>
                
                <p>Three modalities dominate RCC development:</p>
                
                <p><strong>P2X3 Antagonists:</strong> P2X3 remains the most validated mechanism, but only highly selective, taste-sparing agents with ≥30% adjusted efficacy are viable in the U.S.</p>
                
                <p><strong>Kappa/Mu Opioid Modulators (Nalbuphine ER):</strong> Highest efficacy potential; regulatory risk tied to opioid-related concerns and need for robust Phase 3 confirmation.</p>
                
                <p><strong>Alternative Mechanisms:</strong> Includes TRPM8 agonists, sodium channel blockers, NK-1 antagonists, airway hydration. Intriguing but unproven pathways. Unlikely to deliver first-in-class approval without novel trial designs or biomarker stratification.</p>
                
                <p><strong>Digital Pathways:</strong> Meaningful potential both as standalone interventions and in combination with pharmacological drugs. Preliminary data very promising. Trajectory will depend primarily on the pace of adoption of digital therapeutics within health systems.</p>
            </section>
            
            <!-- Digital Inflection Point -->
            <section class="content__section">
                <div class="content__number">04</div>
                <h2 class="content__title">The Digital Inflection Point</h2>
                
                <p>Digital therapeutics (DTx) are emerging as central to the RCC treatment model. The field presents two distinct digital opportunities:</p>
                
                <h4 style="color: var(--forest); margin: 24px 0 12px; font-size: 1.1rem;">Standalone Digital Therapeutics</h4>
                <p>Behavioral cough suppression therapy (BCST) demonstrates <strong>40–88% improvement</strong> in RCTs and is guideline-endorsed but bottlenecked by provider scarcity.</p>
                <ul>
                    <li>Digital delivery via mobile platforms replicates BCST elements</li>
                    <li>Early digital cohorts show ~42% reductions in cough frequency</li>
                    <li>No drug toxicity; large addressable population</li>
                    <li>Japan-first prescription DTx pathways (e.g., Kyorin × Hyfe) create regulatory precedent</li>
                </ul>
                
                <h4 style="color: var(--forest); margin: 24px 0 12px; font-size: 1.1rem;">Combination Therapy (Drug + DTx)</h4>
                <p>Digital augmentation materially strengthens the economics of pharmacologic therapy:</p>
                <ul>
                    <li>Average treatment duration increases from 6–8 months to ~9 months (+20–30%)</li>
                    <li>This yields a <strong>20–44% increase in lifetime value (LTV)</strong> and a 7–8× ROI for manufacturers</li>
                    <li>Objective monitoring provides regulators and payers with real-world evidence on durability</li>
                    <li>Combination approaches may offer differentiation where efficacy deltas are narrow</li>
                </ul>
                
                <p>The drug+DTx model is a high-leverage commercial tool and could become a requirement for payers evaluating chronic symptom management therapies.</p>
            </section>
            
            <!-- Outlook -->
            <section class="content__section">
                <div class="content__number">05</div>
                <h2 class="content__title">Outlook 2026–2035</h2>
                
                <p>Three structural forces will shape the market this decade:</p>
                
                <p><strong>1. Regulatory interpretation of placebo-adjusted efficacy:</strong> Only agents demonstrating clear improvement in objective and subjective cough frequency are likely to be approved in the U.S.</p>
                
                <p><strong>2. Durability and HEOR evidence:</strong> Therapies demonstrating long-term symptom control with measurable QoL and cost offsets will capture payer support.</p>
                
                <p><strong>3. Digital integration:</strong> Objective monitoring and behavioral therapeutics—either standalone or integrated—will expand the market, improve clinical outcomes, and protect persistence-driven revenue.</p>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-card__number">Bull Case</div>
                        <div class="stat-card__label">High-efficacy agents validate; DTx achieves payer acceptance; market expands to >$15B</div>
                    </div>
                    <div class="stat-card stat-card--highlight">
                        <div class="stat-card__number">Bear Case</div>
                        <div class="stat-card__label">Placebo response erodes signal; P2X3 setbacks continue; RCC remains off-label</div>
                    </div>
                </div>
            </section>
            
        </div>
    </main>
    
    <!-- CTA Section -->
    <section class="cta-section">
        <div class="container">
            <h2 class="cta-section__title">Get the Full 52-Page Report</h2>
            <p class="cta-section__text">
                Access pipeline scorecards, scenario models, risk matrices, and detailed strategic positioning insights.
            </p>
            <a href="index.html#gate" class="cta-section__btn">
                <svg viewBox="0 0 24 24"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z"/></svg>
                Download Full Report
            </a>
        </div>
    </section>
    
    <!-- Footer -->
    <footer class="footer">
        <div class="footer__inner">
            <p class="footer__text">
                © 2025 RCC Therapeutics Report. Prepared with support from Hyfe Inc.
            </p>
            <div class="footer__links">
                <a href="index.html">Full Report</a>
                <a href="thesis.html">Thesis</a>
                <a href="https://www.hyfe.com" target="_blank">Hyfe.com</a>
            </div>
        </div>
    </footer>
</body>
</html>
